Original
Effect of mammalian-target-ofrapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database
Takaya Uno, Mitsutaka Takada, Satoshi Yokoyama, Kazuyoshi Kawabata, and Kouichi Hosomi
Price
42.00 $
Volume 60 (2022) p. 477 - 485
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 60 – No. 11/2022 (477-485)
Effect of mammalian-target-ofrapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database
Takaya Uno1#2, Mitsutaka Takada2, Satoshi Yokoyama2, Kazuyoshi Kawabata1, and Kouichi Hosomi2
1Department of Pharmacy, National Cerebral and Cardiovascular Center, Suita, and 2Division of Clinical Drug Informatics, Faculty of Pharmacy, Kindai University, Higashi-Osaka, Japan
Objective: Calcineurin inhibitors (CNIs), including cyclosporine and tacrolimus, are associated with an increased cancer risk. However, whether mammalian target of rapamycin inhibitors (mTORis), including sirolimus and everolimus, decrease the cancer risk in patients receiving CNIs remains uncertain. We aimed to determine whether mTORis are associated with a decreased cancer risk in patients receiving CNIs using data mining of a spontaneous adverse reaction database.
Materials and methods: Disproportionality analysis was conducted using the U.S. Food and Drug Administration Adverse Event Reporting System database (2004 – 2019) with reporting odds ratio and information component being used to indicate a signal.
Results: Data subset analyses indicated that sirolimus and everolimus were not associated with a decreased cancer risk in patients receiving cyclosporine or tacrolimus but were associated with an increased risk of nonmelanoma skin cancer (NMSC) and Kaposi’s sarcoma.
Conclusion: mTORis are not associated with a decreased cancer risk but are associated with a further increase in the risk of NMSC and Kaposi’s sarcoma in patients receiving CNIs. Further studies are necessary to clarify the mechanism underlying the association between mTORis and NMSC or Kaposi’s sarcoma.Correspondence to:
Takaya Uno, PhD
Department of Pharmacy
National Cerebral and Cardiovascular Center
564-8565, Suita, Osaka, Japan
Email: [email protected]
Original
Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases
Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama, and Kazuyoshi Kawabata
Price
42.00 $
Volume 61 (2023) p. 33 - 36
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 61 – No. 1/2023 (33-36)
Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases
Takaya Uno1#2, Kouichi Hosomi2, Satoshi Yokoyama2, and Kazuyoshi Kawabata1
1Department of Pharmacy, National Cerebral and Cardiovascular Center, Suita, and 2Division of Clinical Drug Informatics, Faculty of Pharmacy, Kindai University, Higashi-Osaka, Japan
Objective: To identify the trends in tolvaptan prescription and the association between aging and tolvaptan-induced hypernatremia.
Materials and methods: A health insurance claims database and a spontaneous adverse drug reaction database were used.
Results: Of all patients who had been prescribed tolvaptan, the proportion of patients aged 60 – 79 years and ≥ 80 years was consistent at ~ 40%. Moreover, the prescription frequency of tolvaptan increased over time for patients in the same age groups. The adjusted reporting odds ratio of tolvaptan-induced hypernatremia was 5.54 (95% confidence interval, 3.31 – 9.25) in patients aged ≥ 60 years from among all patients and 2.09 (95% confidence interval, 1.59 – 2.75) in those aged ≥ 80 years from among those aged ≥ 60 years.
Conclusion: It may be necessary to be aware of hypernatremia in elderly patients who are expected to have increased prescriptions of tolvaptan.Correspondence to:
Takaya Uno, PhD
Department of Pharmacy
National Cerebral and Cardiovascular Center
564-8565, Suita, Osaka, Japan
Email: [email protected]
Original
Early acute kidney injury after tacrolimus administration in heart transplant recipients receiving basiliximab induction therapy
Megumi Ikura, Tsutomu Nakamura, Kyoichi Wada, Rikako Nagata, Tomoko Ueno, Kazuyoshi Kawabata, Fumiki Yoshihara, Takuya Watanabe, and Yasumasa Tsukamoto
Price
42.00 $
Volume 62 (2024) p. 525 - 533
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 62 – No. 11/2024 (525-533)
Early acute kidney injury after tacrolimus administration in heart transplant recipients receiving basiliximab induction therapy
Megumi Ikura1, Tsutomu Nakamura2, Kyoichi Wada2, Rikako Nagata1, Tomoko Ueno1, Kazuyoshi Kawabata1, Fumiki Yoshihara3, Takuya Watanabe4, and Yasumasa Tsukamoto4
1Department of Pharmacy, National Cerebral and Cardiovascular Center, Suita, 2Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, 3Department of Hypertension and Nephrology, and 4Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
Objective: In this study, we aimed to analyze the association among the timing of tacrolimus initiation, time required to reach the target blood concentration, and early acute kidney injury (AKI) after tacrolimus administration in heart transplant recipients who received basiliximab induction therapy.
Materials and methods: 88 patients treated with tacrolimus-based immunosuppressive therapy were retrospectively reviewed. Induction therapy was administered to 52 patients. AKI was evaluated within 7 days of tacrolimus administration.
Results: The rate of increase in tacrolimus trough concentration to the target trough concentration of 10 µg/mL early after its administration was set to be similar in the basiliximab induction and non-induction group; 8 and 2 patients developed AKI in the induction and non-induction group, respectively. In the induction group, there was no significant difference in the timing of tacrolimus initiation and the time required to reach the target concentration between patients who developed and did not develop AKI. In contrast, the cumulative incidence of AKI was significantly different between patients with an estimated glomerular filtration rate below and those with an estimated glomerular filtration rate above 43 mL/min/1.73m2 at the start of tacrolimus administration (37.5% and 11.4%, respectively; p = 0.045).
Conclusion: In patients receiving basiliximab induction therapy, the timing of tacrolimus initiation and the time to reach the target concentration are unlikely to be associated with early AKI after tacrolimus administration. However, the recovery of sufficient renal function after heart transplantation is important for determining the start time of tacrolimus.Correspondence to:
Tsutomu Nakamura, PhD, Professor
Education and Research Center for Clinical Pharmacy
Faculty of Pharmacy
Osaka Medical and Pharmaceutical University
4-20-1 Nasahara, Takatsuki 569-1094, Japan
Email: [email protected]
Corrigendum
Corrigendum for the article Int J Clin Pharmacol Ther 2024; 11: 525-533
Megumi Ikura, Tsutomu Nakamura, Kyoichi Wada, Rikako Nagata, Tomoko Ueno, Kazuyoshi Kawabata, Fumiki Yoshihara, Takuya Watanabe, and Yasumasa Tsukamoto
Volume 62 (2024) p. 582 - 582
Abstract
Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 62 – No. 12/2024 – Corrigendum
Corrigendum for the article Int J Clin Pharmacol Ther 2024; 11: 525-533
Megumi Ikura, Tsutomu Nakamura, Kyoichi Wada, Rikako Nagata, Tomoko Ueno, Kazuyoshi Kawabata, Fumiki Yoshihara, Takuya Watanabe, and Yasumasa Tsukamoto
